ClinicalTrials.gg
RecruitingNCT06098430Updated Nov 10, 2026

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

An observational study in Nodular Lymphocyte-Predominant Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital. Recruiting at 7 sites in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital — 6 open to participants now, 13 under way, none of them phase 3. Hodgkin Disease · St. Jude Children's Research Hospital.

Started
2024
with 1 other
Observational
9 of 27
3 open now
Primary completion
2029-02
later than 9 of 12 live
Registered
23rd of 27
by date

Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, this one is one of 2 that started in 2024, is one of 9 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 23rd registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

6 of the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 8 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments.

Primary Objective:

  • To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with NLPHL.

Secondary Objective:

  • To examine differences in baseline and longitudinal changes in PROs based on disease characteristics, disease status, and treatment strategies among adult and pediatric patients diagnosed with NLPHL.
Read the detailed description

The broad aim of this study is to develop the foundational data management infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The study team further aims to elucidate how PROs change over time and how they may be affected by different patient, disease, and treatment characteristics.

03

Conditions studied

  • Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients that meet eligibility

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 8 years
  • Patient or their adult proxy must have verbal and written English language proficiency.
  • confirmed diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL); patients with evidence of transformed lymphoma at diagnosis or subsequent development of transformed lymphoma after diagnosis are eligible.
  • Patients or their adult proxy must be able to provide consent.
  • Patients and/or adult proxy must be able to complete electronic quality of life surveys

Exclusion criteria

Exclusion Criteria

  • Age 7 years or less.
  • Patient or adult proxy does not have verbal and written English language proficiency.
  • Patients with histologic evidence of a composite lymphoma (NLPHL with a concurrent diagnosis of Hodgkin lymphoma, indolent non-Hodgkin lymphoma, or gray zone lymphoma) at diagnosis are not eligible.
  • Inability or unwillingness of research participant or legal guardian/representative to give consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Estimates of response rates

    Percentage of survey completion at different timepoints

    Time frame: At baseline, 3, 6, 9, and 12 months

  2. Patterns of individual per-patient survey completion

    Patterns of individual per-patient survey completion will be described. Non-responders, late responders, and patients with suboptimal item completion rates who require real-time outreach will be queried for individual challenges in completing PRO surveys for iterative improvements to infrastructure.

    Time frame: At baseline, 3, 6, 9, and 12 months

07

Study locations

7 of 7 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Feb 2029, 58 months after the start.

Of 59 non-industry observational studies under Hodgkin Disease, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 149. This study's planned 58 months is close to that.

Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 149.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Feb 2029 and completion Jan 2028 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 24, 2023
StartActual
Apr 4, 2024
Primary completionEst.
Feb 2029was Dec 2026
CompletionEst.
Mar 2030was Jan 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Feb 2029
Nov 10, 2026
Study completion
Jan 31, 2028→Mar 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Dec 31, 2026→Feb 2029
    Study completion Jan 31, 2028→Mar 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06098430
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Apr 4, 2024
Primary completion
Feb 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Valerie Crabtree, PhD
Contact
referralinfo@stjude.org
888-226-4343
Jessi Rogers Blake, BSN,RN,CCRP
Contact
jessi.rogers-blake@stjude.org
901-595-4108
Valerie Crabtree, PhD
principal investigator · St. Jude Children's Research Hospital
Ajay Major, MD, MBA
principal investigator · University of Colorado, Denver
Anna Jones, PhD
principal investigator · St. Jude Children's Research Hospital
Matthew Rees, MD
principal investigator · St. Jude Children's Research Hospital
Jamie Flerlage, MD, MS
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion